Weight Loss in Adults Using Semaglutide (Real-world Study)
Recruiting · NCT07627074 · Observational (researchers observe without assigning treatment) · Lead sponsor: Novo Nordisk A/S
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Initiation of semaglutide for weight management during the study period.
- Age more than or equal to (≥) 18 at treatment initiation
- Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2.
- Other inclusion criteria as defined in the protocol are applicable.
Exclusion criteria
- Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
- Bariatric surgery at baseline.
- Diabetes at baseline.
- Pregnancy at baseline.
Where it is running
2 locations listed across 1 US state.
- Novo Nordisk Investigational Site - Seattle, Washington, United States
- Novo Nordisk Investigational Site - London, United Kingdom